Humanised anti-n-truncated amyloid β monoclonal antibody

US12297261B2 · kind B2 · utility

Assignees

• GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN · DE
• LIFEARC · GB

Inventors

• Thomas Bayer · Igersheim, DE
• Preeti Bakrania · Stevenage, GB
• Sarah Davies · Stevenage, GB
• Alex Brown · London, GB
• Chido Mpamhanga · Harpenden, GB
• David Matthews · Lindon, US
• Mark CARR · Leicester, GB
• Gareth HALL · Leicester, GB

Key dates

• Filing date: Oct 2, 2019
• Grant date: May 13, 2025
• Expiry date: Sep 6, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).